B cell

Comprehensive Review Highlights Importance of Leukine® in Combination with Anti-GD2 Immunotherapy for Treatment of High-Risk Pediatric Neuroblastoma

Retrieved on: 
Wednesday, January 17, 2024

LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.

Key Points: 
  • LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.
  • It also describes why the authors believe it is suboptimal to replace with Leukine with G-CSF in this regimen for mechanistic reasons.
  • Leukine has been studied extensively in combination with dinutuximab and naxitamab leading to improved patient outcomes.
  • As a result, all clinical trials supporting the FDA-approval of dinutuximab and naxitamab included Leukine and both products are labeled for use in combination with GM-CSF.

ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement

Retrieved on: 
Wednesday, January 17, 2024

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.

Key Points: 
  • ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement.
  • The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.
  • Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight.
  • With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

3D Cell Culture Market Size and Share to Surpass USD 8.9 Billion by 2035 | Roots Analysis

Retrieved on: 
Tuesday, January 16, 2024

LONDON, Jan. 16, 2024 /PRNewswire/ -- 

Key Points: 
  • Also, the maintenance of 3D cell culture equipment is complex and requires specialized training or skilled personnel, which enhances the overall cost of installing 3D cell culture.
  • Despite the market restraints, the 3D cell culture market is growing exponentially due to the increasing trend of personalized medicine and ongoing technological advancements to enhance the reproducibility of 3D cell culture-based experiments.
  • Based on the scaffold format, the 3D cell culture market is dominated by scaffold-based format, capturing 46% of the market share by 2035.
  • Based on the key geographical region, North America will dominate the 3D cell culture market, capturing 39% of the overall market share by 2035.

Health Canada Approves UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Retrieved on: 
Tuesday, January 16, 2024

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death –

Key Points: 
  • "Just a single NMOSD attack can have a life-altering impact, including pain, debilitation and irreversible vision loss.
  • Health Canada based its approval of UPLIZNA on results from the N-MOmentum pivotal trial ( 2014-000253-36 ), the largest NMOSD clinical trial to date.
  • UPLIZNA demonstrated a significant reduction in the risk of an NMOSD attack with only two infusions per year, following the initial loading doses.
  • "We can now accurately diagnose NMOSD, which is distinctly different from MS and warrants specific treatment.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024

Retrieved on: 
Saturday, January 13, 2024

EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.

Key Points: 
  • EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.
  • A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Cell Cryopreservation Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024

The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines.
  • For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.
  • Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate.

SMK Electronics to Show New Products Utilizing Advanced Energy Harvesting Technology at CES 2024

Retrieved on: 
Tuesday, January 9, 2024

SMK Electronics Corporation, U.S.A. today announced several new products utilizing the company’s SCPS Energy Harvesting technology.

Key Points: 
  • SMK Electronics Corporation, U.S.A. today announced several new products utilizing the company’s SCPS Energy Harvesting technology.
  • At CES 2024, SMK will be showing these new products and advancements including a Self-Contained Power Supply (SCPS) LoRaWAN® Tracker, and a SCPS Coin Battery designed to replace CR2032 batteries (Booth #52348 Venetian Expo, January 9th-12th, 2024, Las Vegas).
  • “SMK will be showing several truly ground-breaking new technologies at CES 2024, but perhaps the most impactful is our new SCPS Energy Harvesting Technology,” said Paul Evans, President of SMK Electronics Corporation, U.S.A. “Gathering energy from surrounding indoor or outdoor ambient light sources, SCPS stores it internally for use by the host device.
  • “New products at CES this year include SMK’s SCPS Self Contained Power Supply LoRaWAN Tracker, and the SCPS Coin Battery.

Canadian Cancer Society's 9th annual Dry Feb raises funds to support people affected by cancer

Retrieved on: 
Tuesday, January 9, 2024

TORONTO, Jan. 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is challenging people in Canada to "go dry" this February for its 9th annual Dry Feb campaign.

Key Points: 
  • TORONTO, Jan. 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is challenging people in Canada to "go dry" this February for its 9th annual Dry Feb campaign.
  • "Changing attitudes and perceptions around our relationships with alcohol are a new frontier in cancer prevention and healthy living," said Andrea Seale, CEO of the Canadian Cancer Society.
  • In fact, in 2023, over two thirds of Dry Feb participants cited the health benefits of eliminating alcohol as their reason for participating in Dry Feb again.
  • Every day and every dollar will make a meaningful difference in the lives of all those affected by cancer.

Scale Biosciences Announces Progress Across Growing Portfolio of Single-Cell Omics Solutions

Retrieved on: 
Monday, January 8, 2024

“ScaleBio was founded to enable a broad range of single-cell multiomics applications at unprecedented scale without sacrificing data quality.

Key Points: 
  • “ScaleBio was founded to enable a broad range of single-cell multiomics applications at unprecedented scale without sacrificing data quality.
  • “We are thrilled to be shipping the only commercially available whole genome single-cell methylation product and look forward to seeing how researchers use it.
  • In addition, >2,000 PBMCs were sequenced with the methylation kit to generate datasets across all products.
  • The company plans future releases of additional datasets to show the robustness and applicability of its tools with varying sample types.

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today outlined its 2024 corporate strategy to deliver accelerated revenue growth, sustainable research and development, and a clear path to profitability.

Key Points: 
  • ET) --
    SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today outlined its 2024 corporate strategy to deliver accelerated revenue growth, sustainable research and development, and a clear path to profitability.
  • As a result of continued strategic portfolio prioritization, Blueprint Medicines expects a year-over-year decline in operating expenses in 2024.
  • Kate Haviland, Chief Executive Officer of Blueprint Medicines, will present a company overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. PT / 1:30 p.m.
  • A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.